Lonza Group stock
LONN.SWSIXLonza Group AG, HealthcareISIN CH0013841017
63Score 63 out of 100, Neutral
Price and trend
83 / 100
Price history
+20% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 23% above it.
Since July 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 74).
The price is at its 52-week high. Largest decline in 20 years: 79% (August 2008 to June 2012).
Chart figures for advanced users
- SMA 50$716.33
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$653.75
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)74
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$562.38
- The lowest closing price of the last twelve months.
- Resistance$810.24
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Lonza Group AG belongs to the Biotechnology industry (Switzerland) and, with a market value of $56.05B, is number 6 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $7.87B (up 19.2% year on year) and earnings of $1.14B (up 49.2%).
- For fiscal 2026, analysts expect on average revenue of $8.58B (up 9%) and adjusted earnings per share of $22.20.
Show more
- MEQIRI Score 63 out of 100 (Neutral): rank 237 of 714 in Healthcare, median 53.
- The P/E is 43.1 (Biotechnology median 21.3, own median of recent years 36.8).
- Our model puts fair value at $693.12, with the price 15% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for 22 years.
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 54
- Share buybacksShare count down 6% since 2020.
Weaknesses
- Richly valuedP/E 43.1, Biotechnology median 21.3, own median 36.8.Valuation 36
Its standout strengths are momentum and technical analysis, while capital allocation and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among stocks ranked 101 to 1,000.
From 2016 to 2025, 13 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What lowers it
- calm price action
- price near its 52-week high
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $495.09 and expensive above $1,155.21 (uncertainty high, one part of the fair value is more than twice the other).
The two parts of the fair value come to $989.73 (cash-flow model) and $396.51 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 6.1%. At 7.1% the fair value would be $600.29, at 5.1% it would be $828.84.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 4.9% on the twelve months before. Revenue has grown solidly since 2006, at about 6% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 35%, operating 19%, net 15%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 27 Jan 2027in 76 days
- Last reported
- 22 Jul 2026EPS reported $9.91 (expected $10.48)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $22.20+1.1%
- Revenue
- $8.58B0.0%
- Earnings per share
- $26.65+2.0%
- Revenue
- $9.6B+0.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −3.9%2026 core EBITDA margin outlook upgraded to 33% to 34% from above 32%, with CER sales growth of 11% to 12% reconfirmed.
“Based on our strong H1 performance, we are upgrading our full year 2026 CORE EBITDA margin outlook to 33%-34%, while reconfirming our expectation of 11%-12% CER sales growth. In summary, for 2026, you can expect from us the delivery of another full year of strong, profitable growth.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 22 Jul 2026 (fiscal Q2 2026), read by AI.
What happened at Lonza Group
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 63
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- ModernaMRNA $100.63B48
- Regeneron PharmaceuticalsREGN $99.23B81
- UCBUCB.BR $61.8B78
- argenxARGX $61.25B70
- Samsung Biologics207940.KS $49.8B68
- BeOne MedicinesONC $44.88B70
- Revolution MedicinesRVMD $39.08B43
- Celltrion068270.KS $35.32B64
ETFs that hold Lonza Group
Held by 116 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares SLI UCITS ETF (DE)EXI1 | 4.56% | 0.51% | €589.04M |
| Amundi DJ Switzerland Titans 30 UCITS ETF DistC030 | 3.30% | 0.25% | €237.76M |
| Amundi MSCI Europe Ex EMU ESG Selection UCITS ETF Acc540H | 3.07% | 0.30% | €182.66M |
Show 5 more
| Xtrackers Switzerland UCITS ETF 1DXSMI | 3.03% | 0.30% | €2.88B |
| Xtrackers MSCI Europe Health Care Screened UCITS ETF 1CDXSE | 2.90% | 0.17% | €363.6M |
| iShares MSCI Europe Health Care Sector UCITS ETFESIH | 2.90% | 0.18% | €954.9M |
| State Street SPDR MSCI Europe Health Care UCITS ETFSPYH | 2.86% | 0.18% | €653.55M |
| iShares STOXX Europe 600 Health Care UCITS ETF (DE)EXV4 | 2.77% | 0.46% | €729.65M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = CHF 0.8299)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 12 Jun 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.